Update on STAMPEDE data on abiraterone + ADT in M0 patients with HSPC

Three months ago, James et al. presented the overall survival data from the most recently completed arm of the STAMPEDE trial at the annual meeting of the American Society of Clinical Oncology (ASCO). … READ MORE …

What is standard, first-line therapy for men with mHSPC today?

A presentation at the ongoing annual meeting of the European  Society of Medical Oncology (ESMO), in Madrid, Spain, has offered us data comparing abiraterone acetate + prednisone + ADT to docetaxel + ADT in the treatment of men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …

Astellas, Medivation initiate new Phase III ARCHES trial

According to a media release issued today by Astellas Pharma and Medivation, the companies have just initiated a new, Phase III, pivotal trial of enzalutamide in men with advanced prostate cancer. … READ MORE …

Should all patients starting on ADT be on a statin too?

A newly published article in JAMA Oncology has now suggested that adding a statin to a patient’s treatment regimen at initiation of androgen deprivation therapy (ADT) may significantly impact time to disease progression among men diagnosed with progressive, hormone-sensitive prostate cancer. … READ MORE …

Global Phase III trial of enzalutamide in progressive, high-risk prostate cancer

According to a joint media release from Medivation and Astellas earlier today, the companies will soon be initiating an important and major new trial of enzalutamide in men with progressive prostate cancer after first-line therapy. … READ MORE …

New Phase III trial is testing ADT + bicalutamide vs. ADT + TAK-700

It has been brought to our attention that the Southwest Oncology Group (SWOG) has initiated a new, randomized, double-blind, multi-center, Phase III trial designed to compare androgen deprivation therapy (ADT) + bicalutamide (Casodex) to ADT + the investigational drug TAK-700 in men newly diagnosed with metastatic, hormone-sensitive prostate cancer. … READ MORE …

Can CTC levels predict progression of hormone-sensitive prostate cancer?

The levels of circulating tumor cells (CTCs) — as evaluated using Cellsearch technology — is becoming accepted as a prognostic marker for disease progression among men with  metastatic castration-resistant prostate cancer (mCRPC), and may even be accepted soon as a surrogate marker for prostate cancer-specific mortality in clinical trials of new agents. … READ MORE …